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ABSTRACT
Activity of the sodium/iodide symporter (NIS) in
lactating breast is essential for iodide (I
–) accumula-
tion in milk. Significant NIS upregulation was also
reported in breast cancer, indicating a potential
use of radioiodide treatment. All-trans-retinoic acid
(tRA) is a potent ligand that enhances NIS expres-
sion in a subset of breast cancer cell lines and in
experimental breast cancer models. Indirect tRA
stimulation of NIS in breast cancer cells is very
well documented; however, direct upregulation
by tRA-activated nuclear receptors has not
been identified yet. Aiming to uncover cis-acting
elements directly regulating NIS expression, we
screened evolutionary-conserved non-coding
genomic sequences for responsiveness to tRA in
MCF-7. Here, we report that a potent enhancer in
the first intron of NIS mediates direct regulation by
tRA-stimulated nuclear receptors. In vitro as well as
in vivo DNA–protein interaction assays revealed
direct association between retinoic acid receptor-a
(RARa) and retinoid-X-receptor (RXR) with this
enhancer. Moreover, using chromatin immunopre-
cipitation (ChIP) we uncovered early events of NIS
transcription in response to tRA, which require the
interaction of several novel intronic tRA responsive
elements. These findings indicate a complex inter-
play between nuclear receptors, RNA Pol-II and
multiple intronic RAREs in NIS gene, and they estab-
lish a novel mechanistic model for tRA-induced
gene transcription.
INTRODUCTION
In alveolar cells of the lactating mammary gland, the
activity of Na
+/I
– symporter (NIS) is required for the
secretion of I
– in mother’s milk (1,2). I
– in milk is then
used by the newborn in thyroid hormone biosynthesis, and
therefore it has an essential role in postnatal development
of the baby (3). The timing of NIS expression in mammary
epithelia is precisely synchronized with the onset of gesta-
tion and with lactation, and it ends when newborns stop
suckling (2). NIS is not expressed in non-lactating
mammary gland tissue unless experimental animals were
treated with combinations of steroid and lactogenic
hormones (2,4,5). Yet, a functional overexpression of
NIS was detected in transgenic mice bearing experimental
mammary tumors induced by mouse mammary tumor
virus (MMTV) promoter-driven activated Ras and
Erb-B2/neu oncogenes, polyoma middle-T antigen
(PyMT), or cyclooxygenase-2 gene (2,6,7).
Relevant with the human breast cancer, increased NIS
expression was also detected in about 70–80% of ductal
carcinoma in situ and invasive breast cancer samples, as
compared to the absence of NIS expression in healthy
breast samples obtained in reductive mammoplasty oper-
ations (2,8). On the one hand, these results have raised the
possibility that radioiodide may be used for diagnosis and
treatment of breast cancer, as it is routinely used against
thyroid cancer and its metastasis (9). On the other hand,
only a small fraction of these NIS-positive tumors has the
capacity to accumulate radio-labeled substrates of the
symporter (2,4,8), suggesting that further enhancement
of NIS expression or post-translational activation of
NIS are required for an eﬀective use of radio-labeled
substrates for imaging and/or treatment of malignant
breast disease.
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such as retinoids (natural or synthetic analogs of vitamin
A), human chorionic gonadotropin (hCG), dexame-
thasone (Dex) and troglitazone (a PPAR-g ligand), were
identiﬁed as molecules having an upregulatory eﬀect on
NIS expression and I
– transport in the ERa-positive
(ERa+) breast cancer cell model, MCF-7 (6,10–12).
Retinoids have the most robust eﬀect on NIS transcrip-
tion, and among this group of ligands, all-trans-retinoic
acid (tRA) is the most potent as it leads to an increase
up to 10-fold both at the transcriptional level, as well
as at the level of I
  transport (10–12). Moreover, in
immunodeﬁcient mice model with MCF-7 cell xenografts,
systemic tRA treatment stimulated NIS expression and
radioiodide uptake around 15-fold in the implemented
graft (7).
We have previously shown that, tRA induces NIS
expression only in ERa+ mammary cell line models,
and neither basal nor inducible NIS transcription is
observed in ERa-negative (ERa ) mammary cell lines
(13). ERa directly interacts with a responsive element in
NIS promoter, and independent from the presence of
estradiols the presence of ERa is important for maximal
tRA induced NIS transcription (13). tRA stimulates NIS
transcription also in human follicular thyroid carcinoma
cell lines FTC-133 and FTC-238, and in these cells the
eﬀect of tRA is mediated by a RA response element
(RARE) that is located at position –1375 relative to
human NIS start codon (14). Dentice et al. (15) have
shown that the cardiac homeobox transcription factor
Nkx2.5 is induced by tRA, and this factor is involved in
the upregulation of NIS transcription by binding to two
cis-acting elements in NIS promoter.
Conserved transcriptional expression patterns of
orthologous and paralogous genes could reﬂect common
molecular regulatory mechanisms, as well as the presence
of conserved regulatory cis-acting elements. Results sup-
porting this view have previously been published for the
Drosophila homeotic (hox) gene complex (16), and similar
observations were reported for NIS (17). For instance,
when the entire 50-ﬂanking sequences starting from NIS
coding region up to the upstream neighboring gene
(RPL18A) were compared, it was found that the similarity
between rat and human sequences is only 11.8%. Yet, the
similarity ratios of previously established cis-acting
elements that are located in the same sequence are remark-
ably high, for example, in the NIS upstream enhancer
(NUE), which is a strong thyroid-stimulating hormone
(TSH) responsive enhancer that is localized between
 9470 and  9046 on the human NIS and  2611 and
 2230 on the rat Nis is 70% similar (18,19). Again, as
expected, the basal promoter of the human NIS (–475 to
 393) has  72% similarity with the rat Nis promoter (17).
In this study, we initially undertook a comparative
genomics approach in order to identify evolutionary con-
served sequences that could play a role in tRA-dependent
NIS regulation. Subsequently, our experimental studies
resulted in the identiﬁcation of a potent intronic
enhancer, which binds RARa and RXR, and upon stim-
ulation by tRA activates NIS promoter both in vitro and
in vivo. We also show that the initiation of transcription by
tRA involves interactions between several identical RARE
sequences found in multiple introns of the gene and RA
stimulated nuclear receptors in vivo. We present a novel as
well as a rather complex and dynamic interplay between
putative RA responsive cis-acting elements, RNA Pol-II
and RA-stimulated nuclear receptors during NIS
transcription.
MATERIALS AND METHODS
Sequence information and databases
Genomic DNA sequences to be analyzed for DNA con-
servation in non-coding sequences were obtained from the
Genome Browser database at the University of California
Santa Cruz (20). The analysis was performed on 90-kb
sequences from Homo sapiens (Release July 2003; Chr.
19: 17816282-17906905), Rattus norvegicus (release June
2003; Chr. 16: 19018698-19107000) and from Mus
musculus (Release October 2003; Chr. 8: 71152446-
71242000). Annotations for the human sequence were
obtained from the Genome Vista database, and sequences
were aligned with the mVista tool using the human
sequence at the x-axis and at 50% conservation level
and a window length of 75bp.
Polymerase chain reaction ampliﬁcation
of conserved regions
Conserved regions clustered within about 1kb were
ampliﬁed by polymerase chain reaction (PCR) as one
larger fragment and subsequently cloned into the
reporter vector. PCR ampliﬁcation was performed in
25-ml reaction volumes containing 0.8 PCR buﬀer,
3mM MgCl2, 200mM dNTP, 10pmol of each primer
(see Supplementary Table S1 for primer sequences), 5%
DMSO, 1U of Taq DNA polymerase (Roche) and 100ng
of human genomic DNA. Thermal cycler conditions were
an initial denaturation step at 94 C for 4min; a loop cycle
of 94 C, 30s/62 C, 30s/72 C, 40s; and a ﬁnal extension
at 72 C for 7min.
Reporter vector constructs
The reporter pGL3-E1b is a modiﬁed version of the
original plasmid pGL3-Basic (Promega), which contains
the E1b TATA element (50-TCG AGT CTA GAG GGT
ATA TAA TGG ATC-30) between XhoI/BglII sites of
pGL3-Basic; destroying the BglII site while keeping the
XhoI site intact. PCR products containing conserved
regions were cloned into MluI/XhoI sites of pGL3-E1b
to produce the reporter plasmids named clusters (Cl) 1,
2, 3, 4, 5, 6 and 7.
Cluster 3 derivatives containing individual or combined
conserved regions were prepared by restriction endo-
nuclease digestion of internal sequences, or by PCR. The
plasmid Cl3-1 was prepared by removing EspI/XhoI
fragment from cluster 3, likewise plasmids Cl3-pm, Cl3
3-4, Cl3-xp and Cl3-4 were prepared by removing the
PvuII/MluI, the PstI/SmaI, the XhoI/PvuII and the SacI
fragments, respectively. The plasmids Cl.3-2 and Cl3-3
were prepared by cloning PCR product containing each
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Supplementary Table S2. Subsequently, PCR products
were cloned into MluI/XhoI sites of pGL3-E1b.
The plasmid DR2-1del was created by introducing a
490-bp deletion in Cl4Wt, deletion was created using
restriction enzyme digestion with MluI and BalI. MluI
digested overhangs were ﬁlled by incubating the digestion
products with 5U of Klenow fragment of DNA
polymerase I (Fermentas) in the presence of 50mM
dNTP at 37 C for 1h prior to ligation.
The plasmid Cl4-R was prepared by cloning the insert
from Cl4Wt into BamHI and SalI sites downstream of the
luciferase reporter. Cl3-pm was created by removing the
sequence between PvuII and MluI from Cl3. The reporter
Cl4-pm was created by replacing the MluI/PvuII fragment
from Cl3 with KpnI/XhoI fragment containing Cl4 insert.
Finally, Cl34-pm was prepared by cloning the insert from
Cl4 into BamHI/SalI of Cl3-pm.
Site-directed mutagenesis
Site-directed mutagenesis was performed on constructs
harboring the retinoic acid response elements in clusters
3 and 4. Summary of the oligonucleotides used in this
procedure is presented in Supplementary Table S2.
PCR-based mutagenesis was performed in 50-ml reaction
volumes containing 40ng of target plasmid DNA, 1  Pfu
buﬀer, 200mM dNTP mix, 100ng of each primer and
2.5U of Pfu-Turbo DNA polymerase (Stratagene).
Reaction conditions were an initial denaturation step at
95 C for 30s followed by 15 cycles of 95 C for 30s/55 C
for 1min/68 C for 6min and 20s. Following the PCR
reaction the tubes were cooled to 37 C on ice and then
1ml of DpnI (10U/ml; Fermentas) was added and
incubated at 37 C for 1h. Following the DpnI digestion
of the parental (methylated) strand, 5ml were used for
transformation of super-competent E. coli (DH5a) cells.
Plasmids were rescued from single colonies and checked
for the presence of the mutation by automated DNA
sequencing.
Luciferase reporter assay
MCF-7 cells were maintained in high glucose DMEM
(Gibco) supplemented with 10% fetal bovine serum
(FBS), 1% penicillin/streptomycin (P/S) and 1%
L-glutamine (Biochrom), at 37 C in a 5% CO2 incubator.
Cells were transfected with plasmid DNAs using
FuGENE-6 reagent (Roche). FuGENE:DNA ratios
were determined experimentally to be 3:1. Cells were
seeded in 24-well plates in DMEM; so that they would
reach conFuence at the time of the assay. Two days
later, and 1h prior to transfection, cells were washed
twice with phosphate-buﬀered saline (PBS), and the
medium was replaced with DMEM lacking antibiotics.
Transfection was carried out with 200ng of reporter
vector plus 3ng phRL-TK (Promega) to normalize for
transfection eﬃciency. Two days post-transfection,
medium was changed with fresh DMEM containing
1mM tRA (Sigma) and continued incubation for 24h,
dimethyl sulfoxide (DMSO) was used as vehicle control.
Then the cells were harvested and luciferase reporter
assays were performed using the Dual-Glo Luciferase
Assay system (Promega). Luciferase values for all
samples were normalized by ﬁrst subtracting the back-
ground of untransfected control, and then dividing
ﬁreﬂy luciferase values over those of Renilla luciferase.
Fold induction is relative to the value of the empty
vector. Fold stimulation was calculated by dividing the
values of the tRA-stimulated sample by the DMSO
control sample and relative to the vector containing
promoter only control. Experiments were performed at
least three times in duplicates.
Electrophoretic mobility shift assay
Nuclear extracts were prepared using the NE-PER
solution (Nuclear and Cytoplasmic Extraction Reagents
– Pierce Biotechnology). Sub-conﬂuent MCF-7 cells
grown in 150-mm plates were treated with 10-nM E2
(for maximal RARa expression) for 6h and then har-
vested by trypsinization and collected by centrifugation
at 1200r.p.m. Nuclear protein extraction was performed
using 50ml packed cell volume samples according to the
manufacturer’s procedure. Oligonucleotide labeling was
performed using the Biotin 30 End Labeling Kit (Pierce
Biotechnology). The labeling reactions contained
1  TdT reaction buﬀer, 100nM unlabeled oligo, 0.5mM
Biotin-11-UTP and 10U TdT in 50-ml reaction volumes.
Electrophoretic mobility shift assay (EMSA) experiments
were performed using the Lightshift Chemiluminescent
EMSA kit (Pierce Biotechnology) according to the proto-
cols provided. In brief, binding reactions included
1 binding buﬀer, 2.5% glycerol, 5mM MgCl2, 50ng/ml
Poly (dI dC), 0.05% NP-40, 4pmol of unlabeled oligo,
5ml nuclear extract and 20fmol of biotin labeled oligo.
For the super shift reaction 1mg of anti-RARa (C-20,
Santa Cruz) or anti-RXR (F-1, Santa Cruz) antibodies
were included to the reaction just before adding the
Biotin labeled oligos (Supplementary Table S2). Binding
reactions were incubated at room temperature for 40min
and then resolved on a 6% native polyacrylamide gel in
0.5  TBE in a minigel electrophoresis apparatus (dimen-
sions 8 8 0.1cm). After electrophoresis, complexes
were electro-transferred to Hybond-N+ nylon mem-
branes (Amersham), and then cross-linked in the GS
Gene Linker (Bio-Rad) at an energy level of 150mJ.
Chemiluminescent detection of biotin-labeled DNA was
performed according to the supplier’s protocol (Pierce
Biotechnology).
Chromatin immunoprecipitation
MCF-7 cells (in 6-well plates) grown in steroid-free and
phenol-red-free DMEM (Gibco) were treated with 1mM
tRA (Sigma) in the presence of 10nM estradiol (Sigma).
Formaldehyde cross-linking [1% (w/v)] was performed for
10min at room temperature. Cross-linking was terminated
by the addition of glycine to a ﬁnal concentration of
125mM. Cells were scraped in PBS, divided into two
tubes and lysed in 400ml lysis buﬀer [1% SDS, 10mM
EDTA, 50mM Tris–HCl (pH 8.0) and 1 protease inhib-
itor cocktail]. Cell lysates were then sonicated twice in the
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INC.), each for 15min at 4 C using a pulse of 30s and
80% amplitude. Cell lysates were cleared by centrifugation
at 13000r.p.m. for 10min, diluted to 6.1ml in dilution
buﬀer [0.01% SDS, 1.1% Triton X-100, 1.2mM EDTA,
16.7mM Tris–HCl (pH 8.0), 167mM NaCl and
1  protease inhibitor cocktail]. At this point, 100mlo f
chromatin solution was removed and labeled as ‘Input’.
Chromatin solution was precleared by adding 50mlo f
protein A-Sepharose CL-4B (GE Healthcare) as 50%
slurry containing 0.5mg/ml BSA (Sigma), 200mg/ml
sonicated salmon sperm DNA (Sigma) in TE (pH 8.0)
for 60min. at 4 C. Immunoprecipitation was performed
at 4 C for 16h using chromatin immunoprecipitation
(ChIP)-grade antibodies against RARa (H1920, Abcam),
RXR (F-1, Santa Cruz), Pol-II (N-20, Santa Cruz) and
FGFR1 (C-15, Santa Cruz). Then, immunocomplexes
were incubated with 50ml protein A-Sepharose (50%
slurry) for at least 16h at 4 C. Afterwards, beads were
collected, washed four times in wash buﬀer I [0.1%
SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris–HCl
(pH 8.0) and 150mM NaCl], and twice in wash buﬀer II
(0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris–
HCl (pH 8.0) and 500 mM NaCl]. Precipitated DNA (as
well as the inputs) was recovered using a solution of 10%
Chelex (Bio-Rad) and Proteinase K, and was used for
qPCR ampliﬁcation. Primers used for qPCR ampliﬁcation
are presented in the Supplementary Table S3. Quantitative
real-time PCR was performed using iQ
TM SYBR Green
Supermix (BioRad) and ampliﬁcation was performed in
the Mx3005P QPCR System (Stratagene) using the fol-
lowing cycling parameters: 95 C for 10min, then 45 cycles
of 95 C for 15s followed by 64 C for 15s and 72 C for
20s, and a melt curve starting at 55 C with 0.5 C incre-
ments for 80 cycles, except for intron 8 element, annealing
temperature was 58 C. Data was normalized to the back-
ground (No Ab) and calculated as fold enrichment over
the control IgG (FGFR1) applying the formula
[2
 (normalized Ct sample - normalized Ct IgG)]. Parallel PCR reac-
tions were performed for agarose gel electrophoresis
analysis, PCR parameters were an initial denaturation at
95 C for 5min and 19 cycles of 15s at 95 C, 15s at 64 C
and 20s at 72 C. PCR products were resolved on a 2%
agarose gel stained with ethidium bromide. At least three
qPCR reactions in triplicates were performed on two inde-
pendent ChIP experiments.
mRNA expression analysis
A small fraction of the cells used for ChIP analysis was
used for expression analysis. RNA was prepared using the
Nucleospin RNA II kit (Macherey-Nagel) as recom-
mended by the manufacturer. RNA quality was checked
spectrophotometrically and quantiﬁed using NanoDrop
2000 (Thermo Scientiﬁc). Two micrograms of total RNA
were used for cDNA synthesis using the Revert-Aid First
Strand cDNA Synthesis Kit (Fermentas). NIS and
GAPDH primers used for real-time PCR quantiﬁcation
are presented in Supplementary Table S3. Quantitative
real-time PCR was performed as described above.
Cycling parameters were similar with annealing
temperature of 60 C. Quantiﬁcation was performed
using the Ct method. Data represent three qPCR
experiments in triplicates from two independent samples.
Statistical analysis
Statistical signiﬁcance was determined by performing the
Student’s t-test (Figures 4D, 6 and 7A) or paired Student’s
t-test (Figures 2, 3, 4C and 7C) using a 95% conﬁdence
interval; P-values <0.05 were considered signiﬁcant.
RESULTS
Comparative genomics identiﬁes potential cis-acting
elements controlling NIS transcription
We analyzed the conservation of non-coding DNA
sequences of NIS by comparing genomic sequences in
three species, R. norvegicus, M. musculus and H. sapiens.
Conserved sequences at non-coding regions (deﬁned as
windows of 75bp with 50% nucleotide identity) were
identiﬁed in pair-wise alignments using the VISTA
program (21). Figure 1 shows the results of the VISTA
alignment in which the short conserved regions that are
localized in non-coding sequences and that meet the
selected criteria were highlighted in pink. Conserved
regions clustered within 1kb were later studied as single
blocks and they were named as cluster 1, cluster 2, cluster
3 and so forth (Supplementary Table S1). This grouping of
conserved regions facilitated subsequent functional
analyses.
Conserved clusters 3 and 4 respond to tRA in
MCF-7 cells
Identiﬁed individual conserved regions that were located
in clusters varied between 13 (as in cluster 6) and 244bp
(as in cluster 3) in length (Figure 1). We studied tRA
responsive transcriptional activation capacities of these
regions in MCF-7 cells in which, induction of NIS gene
by tRA was previously reported (7,10,13). We ampliﬁed
clusters of interest by PCR using human genomic DNA as
a template, and we cloned these fragments into the
luciferase reporter vector pGL3-E1b as described in
‘Materials and Methods’ section. Previously characterized
NIS upstream enhancer, which contributes to the regula-
tion of this gene in thyroid cells (18,19), was located in the
coding sequence of the neighboring upstream gene,
RPL18A. This region, named as ‘cluster 1’, was also
included in our analysis in order to assess a possible
function of this enhancer in a mammary cell system. All
vector constructs were transiently transfected into MCF-7
cells, which were subsequently treated with either DMSO
(as vehicle control) or 1mM tRA for 24h, and the regula-
tory potentials of these conserved clusters were assessed by
luciferase reporter assays. As a result, we found that only
clusters 3 and 4 signiﬁcantly responded to the tRA
stimulus (Figure 2).
Cluster 3 is a 1.1-kb sequence upstream of the human
NIS, located from -1138 to -42 relative to the transcription
start site (22,23). In a previous study, the tRA
responsiveness of the human NIS promoter was attributed
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this cluster [at  1375 relative to the ATG, (14)]. In order
to assess the functionality of this RARE in MCF-7
cells, we created a mutant version of Cl3, in which we
introduced the same mutation (Figure 3A) that completely
abolished tRA response from this sequence in thyroid cell
lines (14). Interestingly, this mutation had a minor eﬀect
on tRA stimulation of Cl3, reducing the tRA stimulation
by only 7% (Figure 3B), indicating that this RARE is
not the major RA responsive site in MCF-7. This result
suggests the presence of an alternative site for tRA
responsiveness in mammary cell systems. To this end, we
created deletion mutants of Cl3 in reporter plasmids,
which contained individual as well as combined conserved
regions (Figure 3C and results not shown). These con-
structs were then tested for tRA responsiveness using
luciferase reporter assays in MCF-7. Despite intensive
analysis on a relatively large number of overlapping
deletion mutants, a tRA responsive region other than
the previously identiﬁed RARE could not be found in
Cl3 (see Figure 3C for a summary of our results). On
the other hand, removal of conserved region 3–4
( 100bp) has signiﬁcantly reduced the magnitude of
tRA response and the overall transcriptional potential
Figure 1. VISTA plot of sequence conservation in a 90-kb genomic DNA in human, mouse and rat. Percent nucleotide identities between human,
mouse and rat DNA sequences are plotted as a function of position along the human sequence. Peaks of evolutionary conservation in overlapping
exonic sequences are shaded blue. Aligned regions of >50% identity over 75 bases are shaded pink. Lines above each alignment indicate the position
of the conserved cluster selected for PCR ampliﬁcation. Only 80kb of the alignment is shown.
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ments essential for maximum levels of transcription. These
results suggest that tRA responsiveness of Cl3 requires a
synergistic eﬀect of multiple regulatory elements.
A functional RARE is present in the ﬁrst intron of NIS
Cluster 4 is a 774-bp sequence located in the ﬁrst intron
of the human NIS. This cluster is composed of
three conserved regions numbered from 4-1 to 4-3
(Figure 4A). A closer look at the sequence composition
of this cluster revealed the presence of three putative
RAREs. The ﬁrst is a perfect DR2-type consensus
RARE sequence (24) (DR2-1: AGGTCAggAGTTCA)
located in the second conserved region (region 4-2) and
starting at +927 relative to the ATG. The second is a
DR10-type sequence [DR10: AGGTGG(n10)AGGTCA],
located just after the third conserved region (region 4-3)
and starting at +1206 relative to the ATG. The third is,
again, a DR2-type sequence identical to DR2-1 (DR2-2: A
GGTCAggAGTTCA) and is located at +1222 relative to
the start codon, overlapping with the DR10-type sequence
described above (Figure 4A). A series of pGL3-E1b-based
luciferase reporter constructs containing diﬀerent frag-
ments of this intronic region, as well as in vitro
mutagenized versions of putative RARE sequences were
constructed. A summary of mutations created is presented
in Figure 4B. Functional activity of these RARE
sequences was assessed by transient transfections
followed by luciferase reporter assays in MCF-7 cells
treated either with DMSO (as vehicle control) or with
1mM tRA for 24h. In MCF-7 cells transfected with the
wild-type construct, tRA treatment results in an increase
of about 4-fold when compared to cells treated with
DMSO. This result conﬁrmed once again that the
intronic region contains tRA responsive sequences
(Figure 4C; Cl4Wt), which have the capacity to activate
the transcription of the reporter gene. A very small
deletion (3bp) that changed the second half-site of
DR2-2 but left the DR2-1 and DR10 sequences intact
abolished entirely the tRA responsive activity
(Figure 4C; DR2-2del), indicating that DR2-2 has a func-
tional role in ligand responsive activation of reporter
expression. Moreover, when single or double point muta-
tions were introduced by in vitro mutagenesis in each half
site of the DR2-2, the tRA response was completely lost
(Figure 4C; DR2-2mut1 and DR2-2mut2). However,
removal of the DR2-1 region from the construct by
introducing a 490-bp deletion did not make any eﬀect at
all on tRA responsive activity of the reporter, showing
that DR2-1 is fully dispensable for tRA response
(Figure 4C; DR2-1del). Absence of the DR10 element
both in an otherwise wild-type intronic fragment
context, and in the context of a fragment missing the
DR2-1 element (DR2-1del) did not abolish tRA
responsiveness coming from this region (Figure 4C;
DR10mut and DR2-1del/DR10mut), but they had a
minor eﬀect on the magnitude of the response (2- to
3-fold stimulation).
We also investigated the potential of this intronic
RARE to activate transcription through the native NIS
minimal promoter. For this purpose, we constructed
reporter plasmids containing the minimal NIS promoter
(218bp of NIS upstream region between  260bp and
 42bp relative to transcription start site, and capable of
initiating transcription as assessed by functional reporter
assays, Figure 3C) controlled by Cl4 sequence either
upstream of the promoter element or downstream of the
reporter sequence (mimicking its location in the intron of
NIS). Similar constructs were also prepared using the viral
TATA element, E1b. As anticipated, Cl4 signiﬁcantly
activated NIS promoter in response to tRA when posi-
tioned either at the 50 (P<0.0001, n=8) or at 3 0 of the
reporter (P=0.005, n=8), in agreement with the
function of an enhancer (Figure 4D). On the other hand,
regarding E1b promoter activation, Cl4 responded to the
tRA stimulus only when positioned at the 50 of the
promoter element. Altogether these ﬁndings clearly
indicate that the DR2-2 sequence can act as a RA respon-
sive element, and it is the major RARE that is present in
the ﬁrst intron of human NIS.
RARa and RXR physically interact with the intronic
response element DR2-2 both in vitro and in vivo
Retinoids exert their eﬀects by binding to nuclear retinoic
acid receptors (RARs) and retinoid-X-receptors (RXRs),
which in turn interact with cis-acting regulatory elements,
or RAREs, and stimulate transcription of target genes.
Consistently, previous work of Kogai et al. (12) has
indicated that tRA stimulation of human NIS is
mediated by RAR and RXR. In the presence of tRA,
RAR could form homo- or hetero-dimers with RXR,
Figure 2. Conserved clusters 3 and 4 respond to tRA in MCF-7.
Conserved clusters were ampliﬁed by PCR and cloned into the
luciferase reporter plasmid pGL3-E1b. MCF-7 cells were transfected
with all conserved clusters and treated with tRA or DMSO for 24h.
Of the seven clusters analyzed, only clusters 3 and 4 were signiﬁcantly
responsive to tRA treatment. P-values for the tRA-induced samples
were calculated using paired Student’s t-test with 95% conﬁdence
interval, values <0.05 were considered signiﬁcant.
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by physically interacting with RAREs in RA responsive
genes. In order to establish whether RAR and/or RXR
have the potential to bind the DR2-2 element, we
designed oligonucleotide probes corresponding to the
wild-type DR2-2 sequence, or a variant of DR2-2 where
single-point mutations were introduced in each half-site
(Supplementary Table S2). We then studied in vitro
binding capacities of the two nuclear receptors (RARa
and RXR) to these probes by EMSA experiments
(Figure 5). Initially, we have prepared nuclear extracts
from 17-b-estradiol (E2)-treated MCF-7 cells, and we
determined the abundance of both RARa and RXR in
nuclear extracts by immunoblotting (data not shown).
Subsequently, we incubated nuclear extracts with
biotin-labeled probes containing either a consensus
RARE that was known to interact with RARa and
RXR, the wild-type DR2-2 sequences, or the mutant
form of DR2-2. As expected, we have clearly observed
retarded complexes when nuclear extracts were incubated
with probes carrying the consensus RARE, or the novel
element, DR2-2 (Figure 5, lanes 2 and 7). On the other
hand, the introduction of point mutations into DR2-2
half-sites abolished this shift (Figure 5, compare lanes 7
and 12), unequivocally proving that these band shifts were
observed as a result of direct interactions between the
nuclear factors and the DR2-2 element (Figure 5, shown
with bold arrows). A retarded band marked by an asterisk
has indicated a DR2-2 independent interaction between
nuclear proteins and the DNA probe. All bands were
appropriately competed or shifted, conﬁrming the
speciﬁcity of the interactions (Figure 5, lanes 3, 8 and
13). In order to test whether the two nuclear transcription
factors of interest, RARa and RXR, interact with DR2-2,
we have added factor-speciﬁc monoclonal antibodies to
our binding reactions. Both RARa and RXR antibodies
caused a super shift in the consensus RARE and in DR2-2
probe (arrowheads), while they failed to do so when
probes carrying point mutations on DR2-2 were used
(Figure 5, for RARa compare lanes 4, 9 and 14; for
RXR see lanes 5, 10 and 15). These results clearly
indicate direct interactions between the nuclear
Figure 3. Stimulation of conserved cluster 3 is indirect and distinct from that in thyroid cells. (A) Map of Cl3, conserved regions are represented by
boxes labeled 3-1 to 3-4, the previously characterized RARE is indicated by the black box, the wild type and the mutant sequences are shown below
the map. (B) MCF-7 cells were transiently transfected with either the wild type or the mutant construct, cells were treated with tRA or DMSO and
luciferase assays were performed. (C) Several deletion mutants were prepared to study the transcriptional potential in response to tRA stimulation of
individual or combined conserved regions of Cl3. Plasmids were transfected to MCF-7 cells, followed by tRA (or the vehicle DMSO) treatment for
24h, then luciferase assays were performed. The luciferase values were normalized to those of Renilla luciferase; fold induction was calculated relative
to the empty vector. *Numbers above bars indicate the overall fold stimulation by tRA. P-values for the tRA-induced samples were calculated using
paired Student’s t-test with 95% conﬁdence interval, values <0.05 were considered signiﬁcant.
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RARE, DR2-2.
Subsequently, in order to assess whether RARa and/or
RXR occupies the DR2-2 element in response to tRA
in vivo, we carried out a series of ChIP experiments
in MCF-7 cells. In the presence of RARa or RXR
antibodies, a DNA fragment containing the DR2-2
element was precipitated from formaldehyde cross-linked
total cell lysates (Figure 6). In contrast, the unrelated
control IgG against ﬁbroblast growth factor receptor 1
(FGFR1) did not precipitate the DR2-2 element above
background levels (No Ab) of protein-A Sepharose
beads (Figure 6A). We also investigated the presence of
the two nuclear receptors on DR2-1 using the same
Figure 4. A Functional RARE (DR2-2) is present in the ﬁrst intron of NIS.( A) Representation of conserved regions and putative RARE sequences
in cluster 4. The boxes labeled 4-1 to 4-3 represent the position of the three conserved regions; the positions of putative RARE sequences,
transcription start site and the ATG are indicated. Ex 1 and Ex 2 indicate positions of exons 1 and 2, respectively. (B) Sequence representation
of the Cl4 variants used, RARE half sites are capitalized and mutated nucleotides are underlined and bolded, deleted nucleotides are replaced with
dashes. (C) MCF-7 cells were transiently transfected with Cl4Wt or its mutant derivatives, cells were treated with tRA (or DMSO) for 24h and
luciferase reporter assays were performed. Luciferase values were normalized to those of Renilla luciferase and the fold induction is represented
relative to the empty vector. Reporter constructs are presented in the drawing on the left; putative RAREs are indicated by vertical boxes, an X on a
box indicates the RARE being altered. P-values were calculated using paired Student’s t-test with 95% conﬁdence interval, values <0.05 were
considered signiﬁcant. (D) MCF-7 cells were transfected with Cl4 controlling either the viral E1b promoter or the native NIS promoter (fragment
NIS in Cl3-pm, see ‘Materials and Methods’ section). The sequence for Cl4 was located either 50 of the promoter, or 30 of the luciferase reporter.
Luciferase assays were performed as mentioned above. Fold stimulation by tRA was calculated relative to the vector containing only the pro-
moter element. P-values were calculated using Student’s t-test with 95% conﬁdence interval, values <0.05 were considered signiﬁcant. Drawings are
not to scale.
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responsive to tRA stimulation in reporter assays
(Figure 4C), we found that DR2-1 is actually occupied
by both nuclear receptors in MCF-7 cells (Figure 6B),
but with lower abundance when compared to DR2-2
( 50% less). These ﬁndings demonstrate that, endogenous
RARa and RXR bind to both DR2-1 and DR2-2 that are
present in the ﬁrst intron of NIS in vivo, thereby strongly
suggesting that at least part of the regulatory eﬀects of
the two nuclear receptors, RARa and RXR, on NIS
expression in MCF-7 cells were due to a direct interaction
between the receptors and the intronic RAREs (Figure 6).
Initiation of NIS transcription in response to tRA involves
dynamic interactions between multiple intronic elements,
nuclear receptors and the RNA Pol-II
Besides the intronic enhancer identiﬁed above (DR2-2
in intron 1), there exists several other putative intronic
RARE sequences within NIS gene (25). As we found a
functional RARE in intron 1, we were intrigued to study
a possible involvement of other intronic putative RARE
sequences in NIS gene transcription. As nuclear receptors
interact with cognate response elements in a dynamic
manner (26), we decided to study the dynamics of inter-
actions taking place between cis- and trans-acting factors.
To this end, we used ChIP assays to screen for the
involvement of intronic sequences in NIS transcription
in response to tRA treatment in MCF-7 cells (Figure 7).
MCF-7 cells were cultured in charcoal-treated
steroid-free medium lacking phenol-red, and they were
either treated with DMSO, or with tRA for 15, 30 or
60min, and interactions of RARa, RXR and/or RNA
Pol-II with sequences located in introns 1, 5, 7, 8, 12, 13
and 14 (Figure 7) were investigated. Prior to tRA stimu-
lation (time point 0) all intronic sequences, except the one
in intron 8, were engaged in an interaction with basal
transcriptional machinery (based on precipitation of
these sequences with RNA Pol-II, Figure 7A). By 15min
Figure 5. RARa and RXR interacts with the novel intronic RARE in gel retardation assays. Nuclear extracts from E2-treated MCF-7 cells were
incubated with biotin labeled oligonucleotide probes representing a consensus RARE, the wild-type DR2-2 or the mutant variant DR2-2mut
(DR2-2-Mut1-S in Supplementary Table S2). Samples were resolved on a 6% non-denaturing polyacrylamide gel in TBE, transferred to Hybond
N+ membranes and then incubated with streptavidin, and biotin-labeled DNA probes were detected by chemiluminescence. The name of the probe
used in each binding reaction is indicated on the top of each panel. All binding reactions were competed with 200-fold molar excess of the
corresponding unlabeled probe. Arrows point out the nuclear receptor–DNA complexes, while arrowheads point out the super shift. The asterisk
indicates a DR2-2 independent interaction with nuclear proteins. Labeled probes were incubated in the absence of nuclear extract (lanes 1, 6 and 11),
in the presence of nuclear extract alone (lanes 2, 7 and 12), nuclear extract together with an excess of competing unlabeled probe (lanes 3, 8 and 13),
in the presence of RARa antibodies (lanes 4, 9 and 14), or in the presence of RXR antibodies (lanes 5, 10 and 15). Experiments were repeated at least
three times and a representative result is shown.
Figure 6. RARa and RXR occupy the novel intronic element in vivo.
MCF-7 cells grown in DMEM were treated with 1mM tRA and used
for ChIP analysis using RARa and RXR speciﬁc antibodies. (A) DNA
isolated from immunocomplexes was used as a template for PCR
ampliﬁcation using primers speciﬁc for DR2-2. PCR products were
resolved on a 2% agarose gel (containing Ethidium bromide) and
visualized on a UV transilluminator, RARa; anti-RAR-a Ab
precipitated DNA, RXR; anti-RXR Ab precipitated DNA, FGFR1;
anti-FGFR1 Ab precipitated DNA, No Ab; bead-only control, and
-PCR is a negative control with H2O as a template. (B) Quantitative
PCR was performed using immunoprecipitated DNA using DR2-1 and
DR2-2 speciﬁc primers. Ct values were normalized to background levels
of bead-only controls (No Ab) using 2
(dCt). Data are represented as fold
enrichment compared to IgG control. *P-values were calculated using
Student’s t-test (average of three experiments) with 95% conﬁdence
interval, values <0.05 were considered signiﬁcant.
3180 Nucleic Acids Research, 2010,Vol.38, No. 10Figure 7. Nuclear receptors and RNA Pol-II interact with NIS intronic elements in a dynamic manner during the initiation of transcription. MCF-7
cells grown in steroid-free and phenol-red-free DMEM were treated either with DMSO (time 0) or with 1mM tRA for 15, 30 and 60min and used for
ChIP analysis using RARa and RXR and RNA Pol-II speciﬁc antibodies. (A) DNA isolated from immunocomplexes was used for quantitative PCR
using primers described in Supplementary Table S3. Ct values were normalized to background levels of bead-only controls. Data are represented as
fold enrichment compared to IgG control. (B) mRNA was isolated from a fraction of the cells used for ChIP analysis above. Two micrograms
of total RNA was converted to cDNA and used for quantitative real-time PCR. Expression was normalized to the levels of GAPDH using the Ct
method and presented as relative fold induction compared to DMSO-treated samples. (C) Schematic representation of ChIP data depicting the
events of transcription initiation of NIS in response to tRA stimulation. Arrow heads indicate the position of the intronic element investigated,
vertical small lines represent NIS exons, numbers below indicate introns studied, asterisks above numbers indicate identical sequences. Parallelograms
with question mark represent unidentiﬁed interacting proteins. DR, direct repeat; ER, everted repeat. Statistical signiﬁcance was determined by
performing the Student’s t-test (Figure 7A) or paired Student’s t-test (Figure 7C) using a 95% conﬁdence interval; P-values <0.05 were considered
signiﬁcant.
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they were replaced by RARa (30min), with strong appear-
ance together with RNA Pol-II on the element from intron
7 (Figure 7A). This presence of RARa persists at 60min
post-stimulation in the absence of RXR, accompanied by
an acute increase in mRNA levels (Figure 7B). It appears
that interactions with transcription machinery are sus-
tained by sequences in intron 7 (30 and 60min.) and in
intron 14 (60min.). Figure 7C recapitulates the dynamic
events taking place during initiation of transcription in
response to tRA stimulation.
DISCUSSION
The identiﬁcation of elements that control NIS regulation
in mammary gland cells is of particular importance in the
context that mammary-tumor-speciﬁc stimulation of NIS
activity followed by radioiodide substrate (
131I,
123Io r
99mTcO4) administration could have an important poten-
tial as a novel alternative in the diagnosis and treatment
of breast tumors (2,7,8,17,27). Yet, in a recent publication
(28), it was reported that NIS-related intracellular staining
in immunohistochemistry experiments on thyroid cancers
was due to non-speciﬁc binding of the antibodies. These
authors also conclude that the intracellular signal in breast
tumors might not always be speciﬁc. Therefore, in our
opinion, establishing clinical methods of increasing
expression levels of NIS would be essential if the activity
of this symporter is to be used for a radio-labeled
substrate-based diagnosis and therapy of a large set of
breast tumors (29,30). In a series of publications, Kogai
et al. (7,17,25,31) has demonstrated that tRA stimulates
NIS expression and the selective cytotoxic eﬀect of
radioiodide both in MCF-7 cells as well as in
MCF-7-derived xenografts in nude mice. Yet, the molec-
ular mechanisms of tRA eﬀect on NIS in mammary gland
cells are not completely revealed. Although tRA
upregulates both rodent and human NIS expression at
the transcriptional level in a variety of thyroid and
mammary gland cell lines, molecular mechanisms and
elements that were reported to mediate tRA responsive
NIS regulation varied depending on the organism and
the cell origin. A better understanding of molecular deter-
minants, mechanisms and ligands that have a role in NIS
regulation would be essential for successful implementa-
tion of possible NIS-activity-based novel methods for the
management of malignant breast diseases. In this respect,
our description regarding the molecular interplay between
retinoid receptors, intronic cis-acting elements and RNA
Pol-II brings important clariﬁcations about precise molec-
ular mechanisms and interactions controlling tRA-
dependent NIS gene upregulation (see below).
In an initial eﬀort to identify mammary-gland-speciﬁc
enhancers of NIS, we adopted a comparative genomics
approach followed by functional assays of conserved
DNA sequences in diﬀerent cell types (data not shown).
As widely appreciated, interspecies genome comparisons
were in general very useful for a rather accurate prediction
of protein encoding genes in diﬀerent organisms (32).
On the other hand, prediction of gene regulatory regions
by genome comparisons tends to be relatively more diﬃ-
cult as they tolerate much more sequence divergence than
coding sequences while retaining their original function.
Yet, several reports have indicated that interspecies
genome comparisons of close relatives could lead to
correct predictions of regulatory sequences (33–35). A
similar comparative analysis of a 90-kb region, including
and ﬂanking NIS loci in mice, rat and human genomes,
followed by functional tests in MCF-7 cells, has led us to
identify a novel tRA responsive region in the ﬁrst intron of
the human NIS.
A conserved 50 upstream region of the human NIS
(referred to as cluster 3 in this work) contains a tRA
responsive element that was previously identiﬁed as a
RARE in human follicular thyroid carcinoma cell lines,
FTC-133 and FTC-238 (14). As expected, we have
observed that this region has a remarkable tRA responsive
regulatory capacity (Figure 2) in MCF-7 cells.
Surprisingly, point mutations that were shown to abolish
tRA responsiveness of this element in thyroid cells (14)
had no signiﬁcant suppressive eﬀect on tRA stimulation
in MCF-7 cells (Figure 3B). Our intensive search both by
bioinformatics and by experimental methods, as well as
studies carried out by other groups (25), did not reveal
another RARE in this region. This could imply that
ﬁrst, the mechanism of RA stimulation of human NIS
expression in mammary cell models is distinct from that
of thyroid cells; and, second, the stimulatory eﬀect of RA
on this sequence is actually an indirect one. Moreover,
analysis of overlapping deletion mutations in Cl3 did
not reveal any RA responsive sequence (Figure 3C), sug-
gesting that RA stimulation of the human NIS gene
requires the synergistic eﬀect of multiple factors.
Indirect stimulation of NIS by tRA was previously
reported; tRA was shown to upregulate the rat Nis
promoter in MCF-7 cells by activating the homeobox-
containing transcription factor, Nkx2.5 (15). In this cell
line, tRA treatment stimulates the expression of this
NK2-type transcription factor, which in turn, activates
Nis promoter by binding to two cis-acting elements
located at  446 and  154 relative to ATG (15). Despite
extensive search for similar binding sites in the human NIS
locus, Nkx2.5 responsive cis-acting sequences were not
found (data not shown). In a more recent study, Kogai
et al. (25) described an indirect eﬀect of RA on NIS
expression that is mediated by IGF-1/PI3K signaling
pathways in MCF-7 but not in the rat normal thyroid
cell line FRTL-5. In MCF-7 cells, RA exerts its eﬀect by
activating PI3K signaling pathways, which result in the
activation of an unknown transcription factor, leading
to an enhanced NIS expression (36). It would be interest-
ing to ﬁnd out whether the binding site of this
yet-uncharacterized factor maps in Cl3 or not.
Intronic sequences could contain motifs and cis-acting
elements with varying functions, such as exon/intron rec-
ognition, regulation of alternative splicing events, activa-
tion of transcription, stimulation of polyadenylation and,
surprisingly enough, in certain cases elements regulating
the stability of encoded proteins (37–42). In this report,
we describe a novel enhancer that is located in intron 1,
and that mediates retinoic acid responsive NIS gene
3182 Nucleic Acids Research, 2010,Vol.38, No. 10expression. We have initially shown evidences for a direct
interaction between RARa/RXR and a novel RARE
within the ﬁrst intron of the human NIS in MCF-7 cells
(Figures 5–7). This DR-2 type RARE (DR2-2) was func-
tional in reporter assays and had the capacity to activate
both the native NIS promoter (regardless of position or
orientation) as well as the viral E1b TATA element
(Figure 4D). Recently, Kogai et al. (25) reported
putative RARE sequences present within several introns
of the human NIS, including elements found in the ﬁrst
intron, but they could not attribute a functional role to
these elements (25). Thus, it seems that other than its
native promoter, NIS intronic enhancer could activate
only a subset of heterologous promoters. Interestingly,
another DR-2-type element (DR2-1) of identical
sequence in the same intron was occupied by tRA
stimulated nuclear receptors in vivo despite being
non-responsive to tRA in reporter assays. The diﬀerence
in the regulatory potential of these sequence-wise identical
elements in intron 1 could be related to initial (time 0) and
persistent (60min) interactions with RARa that we
observe in DR2-2 but not DR2-1 (Figure 7A). This
temporal regulation of RARa interaction with its
cognate response elements could well be governed by
epigenetic factors modifying local chromatin structure of
this region. Related to this, we have clearly observed
tri-methylation of H3K4 residues both on DR2-1,
DR2-2 as well as on other intronic RAREs (see below,
and also Supplementary Figure S1), a characteristic
histone H3 modiﬁcation found at enhancer regions of
transcriptionally active genes (43). We have previously
shown that tRA-upregulated NIS expression is restricted
to ERa-positive mammary gland cell lines. In the absence
of ERa, neither NIS promoter, nor the luciferase reporter
gene under control of cluster 3 were stimulated in response
to tRA stimulation, even though tRA signaling was
operative in these cells (13, and Supplementary Figure
S2). Re-introduction of ERa in previously ERa ( ) cells
was required for the recovery of NIS expression (13). It is
therefore plausible to anticipate that intronic elements
that were described in this work could only stimulate ini-
tiation of NIS gene transcription only in the presence of
active ERa.
Our ChIP assays have revealed that at the onset of NIS
gene transcription, sequences located in introns 1, 5, 7, 8,
12, 13 and 14 (Figure 7) interact temporally with nuclear
receptors and with RNA Pol-II. Interestingly, all intronic
elements (except the one in intron 8) were found to
interact intensively with RNA Pol-II in the absence of
ligand, tRA (Figure 7A and C), which might keep the
polymerase ready for the initiation. With the tRA-
dependent onset of transcription, interactions between
cis-acting sequences and RNA Pol-II become undetectable
in our assay system, and in the ﬁrst 15min of tRA induc-
tion RXR solely occupies all intronic positions
(Figure 7C), indicating the early role of this trans-acting
factor in tRA dependent transcription. At later time
points (30 and 60min) while mRNA levels increase in a
steady manner (Figure 7B), interactions between
sequences in intron 7 and RNA Pol-II (and later in
intron 14 and RNA Pol-II) becomes detectable once
again, suggesting frequent interactions between general
transcription apparatus and elements in intron 7 and 14
during maximal levels of transcription (Figure 7A–C).
At the same time points, RARa replaces RXR and
dominates interactions in intronic sites, which implies
the principal role of RARa at relatively late stages of
tRA-dependent transcription initiation. Positions of
intronic sequences found to interact with the RNA
Pol-II and tRA-stimulated nuclear receptors matches
exactly with locations where H3K4 tri-methylations were
observed (Supplementary Figure S1). In fact, in most
cases, persistent RARa interactions at later stages
(30–60min) with intronic elements coincide with increased
H3K4 tri-methylation (Figures 7 and S1). Nuclear recep-
tors, including RARa and RXR, are well known to recruit
histone-modifying co-regulators facilitating conversion
of chromatin regions to transcriptionally permissive
states (44). For instance, MLL5, which is a histone
lysine methyltransferase, was recently described to be
one of the H3K4 modifying enzymes enhancing RARa-
dependent gene transcription (45); one of the epigenetic
mechanisms that could also operate during NIS
expression.
Earlier work and results presented in this manuscript
clearly indicate that molecular mechanisms presiding
NIS expression involve a number of classical and
intronic elements that regulate temporal and spatial
expression, and they are likely to be more complex than
previously anticipated. Future experiments will show
whether the activities of intronic enhancers lead also to
a tissue- or cell-type-speciﬁc regulation of NIS. A better
understanding of this mechanism of regulation, as well as
the ability to selectively enhance NIS expression in tumor
cells will, eventually, be of great importance for potential
future applications in breast cancer diagnosis and
treatment.
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